Revolution Medicines, Inc.
RVMD
주식 순위
#579
Revolution Medicines, Inc. is a precision oncology firm operating in the... Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
주가
$196.16
시가총액
$42.04B
변동 (1일)
7.69%
변동 (1년)
263.19%
국가
US
거래 Revolution Medicines, Inc. (RVMD)
카테고리
Healthcare
Revolution Medicines, Inc. (RVMD)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 15.66
Revolution Medicines, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 15.66입니다. 2023년 말 기준 P/B 비율은 1.78였습니다.
Revolution Medicines, Inc.의 P/B 비율 기록 (2017 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 15.66 | 383.31% |
| 2024 | 3.24 | 82.27% |
| 2023 | 1.78 | -36.60% |
| 2022 | 2.80 | -7.84% |
| 2021 | 3.04 | -45.25% |
| 2020 | 5.55 | -19.62% |
| 2019 | 6.91 | -36.63% |
| 2018 | 10.91 | -95.31% |
| 2017 | 232.64 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 6.251 | -60.08% |
US
|
|
| 13.2547 | -15.36% |
US
|
|
| 4.208 | -73.13% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -60.52% |
NL
|
